Talhouk Aline, Hoang Lien N, McConechy Melissa K, Nakonechny Quentin, Leo Joyce, Cheng Angela, Leung Samuel, Yang Winnie, Lum Amy, Köbel Martin, Lee Cheng-Han, Soslow Robert A, Huntsman David G, Gilks C Blake, McAlpine Jessica N
Department of Pathology and Laboratory Medicine, University of British Columbia and BC Cancer Agency, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Gynecol Oncol. 2016 Oct;143(1):46-53. doi: 10.1016/j.ygyno.2016.07.090. Epub 2016 Jul 14.
Categorization and risk stratification of endometrial carcinomas is inadequate; histomorphologic assessment shows considerable interobserver variability, and risk of metastases and recurrence can only be derived after surgical staging. We have developed a Proactive Molecular Risk classification tool for Endometrial cancers (ProMisE) that identifies four distinct prognostic subgroups. Our objective was to assess whether molecular classification could be performed on diagnostic endometrial specimens obtained prior to surgical staging and its concordance with molecular classification performed on the subsequent hysterectomy specimen.
Sequencing of tumors for exonuclease domain mutations (EDMs) in POLE and immunohistochemistry for mismatch repair (MMR) proteins and p53 were applied to both pre- and post-staging archival specimens from 60 individuals to identify four molecular subgroups: MMR-D, POLE EDM, p53 wild type, p53 abn (abnormal). Three gynecologic subspecialty pathologists assigned histotype and grade to a subset of samples. Concordance of molecular and clinicopathologic subgroup assignments were determined, comparing biopsy/curetting to hysterectomy specimens.
Complete molecular and pathologic categorization was achieved in 57 cases. Concordance metrics for pre- vs. post-staging endometrial samples categorized by ProMisE were highly favorable; average per ProMisE class sensitivity(0.9), specificity(0.96), PPV(0.9), NPV(0.96) and kappa statistic 0.86(95%CI, 0.72-0.93), indicating excellent agreement. We observed the highest level of concordance for 'p53 abn' tumors, the group associated with the worst prognosis. In contrast, grade and histotype assignment from original pathology reports pre- vs. post-staging showed only moderate levels of agreement (kappa=0.55 and 0.44 respectively); even with subspecialty pathology review only moderate levels of agreement were observed.
Molecular classification can be achieved on diagnostic endometrial samples and accurately predicts the molecular features in the final hysterectomy specimens, demonstrating concordance superior to grade and histotype. This biologically relevant information, available at initial diagnosis, has the potential to inform management (surgery, adjuvant therapy) from the earliest time point in cancer care.
子宫内膜癌的分类和风险分层并不完善;组织形态学评估显示观察者间存在较大差异,且转移和复发风险只能在手术分期后才能得出。我们开发了一种用于子宫内膜癌的主动分子风险分类工具(ProMisE),该工具可识别出四个不同的预后亚组。我们的目的是评估是否可以对手术分期前获取的诊断性子宫内膜标本进行分子分类,以及其与后续子宫切除标本上进行的分子分类的一致性。
对60例患者分期前后的存档标本进行POLE外切酶结构域突变(EDM)的肿瘤测序以及错配修复(MMR)蛋白和p53的免疫组织化学检测,以识别四个分子亚组:MMR-D、POLE EDM、p53野生型、p53异常(abn)。三名妇科亚专业病理学家对一部分样本进行组织学类型和分级判定。通过比较活检/刮宫标本与子宫切除标本,确定分子和临床病理亚组判定的一致性。
57例病例实现了完整的分子和病理分类。ProMisE对分期前后子宫内膜样本进行分类的一致性指标非常理想;每个ProMisE类别平均敏感性为0.9,特异性为0.96,阳性预测值为0.9,阴性预测值为0.96,kappa统计量为0.86(95%CI,0.72 - 0.93),表明一致性极佳。我们观察到“p53异常”肿瘤(预后最差的组)的一致性水平最高。相比之下,分期前后原始病理报告中的分级和组织学类型判定仅显示出中等程度的一致性(kappa分别为0.55和0.44);即使经过亚专业病理审查,也仅观察到中等程度的一致性。
可以对诊断性子宫内膜样本进行分子分类,并准确预测最终子宫切除标本中的分子特征,显示出优于分级和组织学类型的一致性。这种在初始诊断时即可获得的生物学相关信息,有可能在癌症治疗的最早时间点为治疗管理(手术、辅助治疗)提供参考。